Akorn Receives Second Warning Letter In Six Months
Executive Summary
You may also be interested in...
Akorn's Delay Moving Three Generics To OTC Leads To $7.9M Settlement In Medicare Billing Complaint
Akorn agrees with DoJ to pay $7.9m to settle allegations it deliberately sold three as Rx three ingredients moved to OTC. Mislabeling led Medicare Part D to pay for the drugs for around a year despite the products not being eligible for coverage.
Akorn Pays Out $7.9m In Medicare Fraudulent Billing Case
Akorn has agreed to pay out $7.9m to settle allegations that it deliberately sold three generic drugs as prescription-only when they should have been classed as over-the-counter, in a deal with the US Department of Justice. The mislabeling led Medicare Part D to pay out for the drugs for around a year despite the products not being eligible for Medicare coverage.
Beleaguered Akorn Files For Bankruptcy
Akorn and its subsidiaries in the US have gone ahead with a Chapter 11 bankruptcy filing, paving the way for an in-court sale of the business and bringing the curtain down for now on the story of one of the hottest generic injectable properties of the last decade.